Novacyt

ALNOV

FR0010397232

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 03:10:01 2024-04-18 am EDT			5-day change	1st Jan Change
0.786 ^EUR	+10.08%		+32.71%	+9.26%

Apr. 11	Yourgene CEO to become head of Novacyt after acquisition	AN
Apr. 11	Novacyt: changes to the Board of Directors	CF

Novacyt S.A. Reiterate Revenue Guidance for the Full Year 2021

August 18, 2021 at 02:00 am EDT

Novacyt S.A. reiterates revenue guidance of £100 million for the full year 2021, excluding DHSC revenues, as announced on 22 June 2021.

Latest news about Novacyt

Yourgene CEO to become head of Novacyt after acquisition	Apr. 11	AN
Novacyt: changes to the Board of Directors	Apr. 11	CF
Novacyt's New CEO to Start May	Apr. 11	MT
Novacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024	Apr. 11	CI
Novacyt S.A. Announces CEO Changes, Effective on May 1, 2024	Apr. 11	CI
FTSE 100 Closes Up 0.9%, Lifted by BP	Feb. 06	DJ
Novacyt says talks to sell Taiwan laboratory are terminated	Feb. 06	AN
Novacyt: Taiwanese laboratory retained	Feb. 06	CF
Novacyt's Discussions for Taiwanese Unit Sale Fall Through	Feb. 06	MT
Treatt revenue falls; Secure Trust profit picks up	Jan. 25	AN
Novacyt appoints new CFO	Jan. 02	CF
Novacyt promotes Finance Director Steve Gibson to CFO	Jan. 02	AN
Novacyt Names Finance Director as New CFO	Jan. 02	MT
Novacyt notes delay of divestment as awaits approvals	Dec. 21	AN
FTSE 100 Closes Down 0.3% Dragged by Oil Stocks	Dec. 21	DJ
Novacyt: sale to Taiwan not finalized before 2024	Dec. 21	CF
Novacyt Delays Closure of Yourgene Health Taiwan's Sale	Dec. 21	MT
Actual Experience appoints administrators	Nov. 07	AN
Novacyt Receives EU Certification for Cancer Enzyme Deficiency Diagnosis; Shares Soar	Nov. 07	MT
Novacyt S.A. Announces IVDR Certification for DPYD Genotyping Assay	Nov. 07	CI
Transcript : Novacyt S.A., H1 2023 Earnings Call, Sep 28, 2023	23-09-28
EARNINGS: Dekel hails palm oil operation; Science in Sport revenue up	23-09-28	AN
Earnings Flash (NCYT.L) NOVACYT Reports H1 Loss GBP-0.12	23-09-28	MT
Earnings Flash (NCYT.L) NOVACYT Posts H1 Revenue GBP3.3M	23-09-28	MT
Novacyt S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI

Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for laboratories.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q4 2023 Earnings Release (Projected)

More about the company